NasdaqGS:ACADBiotechs
A Look At Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX US Launch
Why DAYBUE STIX Matters for ACADIA Shareholders
ACADIA Pharmaceuticals (ACAD) recently reported broad US availability of DAYBUE STIX, a bioequivalent powder formulation of trofinetide for Rett syndrome, following late 2025 FDA approval, drawing fresh attention to the company.
This launch arrives as ACADIA has been beating earnings forecasts in recent quarters, which has kept analyst and investor interest elevated around the stock and its rare disease portfolio.
See our latest analysis for...